NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

(Nasdaq:NURO) shares are trending higher this morning on FDA news! The stock is up more than30% in heavy trading. Price action around $4.11 as of writing this.

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq:NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.

https://www.globenewswire.com/news-release/2022/05/19/2447000/0/en/NeuroMetrix-Reports-that-Quell-Wearable-Neuromodulation-Device-has-Received-FDA-De-Novo-Authorization-as-First-Non-Pharmacological-Treatment-for-Fibromyalgia.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.